Membreno Jaime H, Brown Melissa M, Brown Gary C, Sharma Sanjay, Beauchamp George R
Center for Evidence-Based Health Care Economics, Flourtown, Pennsylvania 19031, USA.
Ophthalmology. 2002 Dec;109(12):2265-71. doi: 10.1016/s0161-6420(02)01286-1.
Evaluation of the incremental cost-effectiveness of therapy for amblyopia.
Cost-utility reference-case analysis.
A cost-utility analysis was performed from a third-party insurer perspective by using decision analysis, evidence-based data from the literature, and patient preference-based time trade-off utility values.
Patient-derived time trade-off ocular utility values and the American Academy of Ophthalmology Preferred Practice Pattern guidelines for the treatment of amblyopia.
Treatment of childhood amblyopia using medical and surgical therapies per the American Academy of Ophthalmology Preferred Practice Pattern.
Dollars (year 2001 nominal U.S. dollars) expended per quality-adjusted life-year ($/QALY) gained.
Treatment for amblyopia resulted in a $/QALY gained of $2281 with a discount rate of 3% for costs and outcomes. Sensitivity analysis, varying costs and utility values by 10%, resulted in a $/QALY gained range from $2053 to $2509.
When compared with other interventions in health care, therapy for amblyopia seems to be highly cost-effective. This information is increasingly important for health care policy makers.
评估弱视治疗的增量成本效益。
成本效用参考案例分析。
从第三方保险公司的角度进行成本效用分析,采用决策分析、文献中的循证数据以及基于患者偏好的时间权衡效用值。
患者提供的时间权衡眼部效用值以及美国眼科学会弱视治疗首选实践模式指南。
按照美国眼科学会首选实践模式,采用药物和手术疗法治疗儿童弱视。
每获得一个质量调整生命年($/QALY)所花费的美元数(2001年名义美元)。
弱视治疗每获得一个质量调整生命年的成本效益比为2281美元,成本和结果的贴现率为3%。敏感性分析中,成本和效用值变动10%,每获得一个质量调整生命年的成本效益比范围为2053美元至2509美元。
与医疗保健中的其他干预措施相比,弱视治疗似乎具有很高的成本效益。这一信息对医疗保健政策制定者越来越重要。